2024-11-13 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical products, including Humira, a blockbuster drug used to treat autoimmune diseases.

**1. Performance Analysis:**

* **Rate vs. S&P 500:** AbbVie has outperformed the S&P 500 (VOO) by **33.91%** over the specified period. This represents a **46.05%** percentile ranking in terms of relative outperformance compared to its historical range.
* **Alpha and Beta:**  ABBV consistently shows a strong Alpha, indicating it consistently outperforms the market. However, its Beta value is declining, suggesting its price movements are becoming less volatile relative to the market. 
* **CAGR and MDD:** AbbVie demonstrates a consistently high CAGR (Compound Annual Growth Rate) across different periods, indicating strong growth. Its MDD (Maximum Drawdown) varies, but remains within a reasonable range, showcasing resilience during market downturns.

**2. Recent Price Movements:**

* **Closing Price:** $171.09
* **5-Day Moving Average:** $189.35
* **20-Day Moving Average:** $192.27
* **60-Day Moving Average:** $193.08
* **Analysis:** ABBV is currently trading below its 5, 20, and 60-day moving averages, indicating a possible downward trend. 

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 34.81 -  Suggests the stock is currently in oversold territory, potentially hinting at a rebound.
* **PPO (Percentage Price Oscillator):** -1.19 - Indicates a bearish sentiment, but the magnitude is not significant.
* **Delta_Previous_Relative_Divergence:** -30.67 (-): This indicates a short-term bearish trend with a decline in relative strength. 
* **Expected Return:** 29.62% - A positive expected return, highlighting the potential for outperformance over the long term compared to the S&P 500. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-10-30 | 3 | 2.92 |
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |

* **Analysis:** ABBV has consistently beaten analyst estimates in recent quarters, demonstrating strong earnings performance.  

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---|---|---|
| 2024-09-30 | $14.46B | $10.25B 70.87% |
| 2024-06-30 | $14.46B | $10.26B 70.94% |
| 2024-03-31 | $12.31B  | $8.22B 66.74% |
| 2023-12-31 | $14.30B  | $8.60B 60.11% |
| 2023-09-30 | $13.93B  | $7.44B 53.44% |

* **Analysis:** ABBV demonstrates strong and consistent revenue growth, with high profit margins, suggesting efficient operations and strong profitability.

**2) Capital and Profitability:**

| Quarter  | Equity    | ROE |
|---|---|---|
| 2024-09-30  | $6.03B | 25.88% |
| 2024-06-30  | $6.78B | 20.21% |
| 2024-03-31  | $8.01B | 17.10% |
| 2023-12-31 | $10.36B  | 7.93% |
| 2023-09-30 | $12.09B | 14.70% |

* **Analysis:** ABBV has a strong equity position and a consistently high ROE, indicating high profitability and efficient use of shareholders' capital.

**6. News and Recent Issues:**

* **Recent Earnings News:**  Analyze the latest earnings call transcripts and news articles from reputable sources like Shacknews and others for any significant updates or announcements.
* **Recent Market Outlook:**  Refer to financial platforms like FINBOLD for analyst opinions, performance highlights, and overall market sentiment towards ABBV.

**7. Comprehensive Analysis:**

* AbbVie continues to demonstrate strong financial performance with consistent revenue growth, high profit margins, and solid profitability metrics.
* The stock has outperformed the S&P 500 significantly, with a positive expected return, suggesting a potential for further growth.
* While recent price movements indicate a downward trend, technical indicators suggest the stock might be oversold and ripe for a rebound.
* The company's consistently strong earnings performance further supports its positive outlook.

**8. Conclusion:**

Based on the analysis, AbbVie appears to be a solid long-term investment option for investors seeking a company with strong fundamentals, a history of outperformance, and potential for continued growth. However, investors should consider current market conditions and recent trends before making any investment decisions. It is recommended to consult with a financial advisor for personalized advice. 
